Thus, ISP treatment upregulated the release of MMP2 in OPCs,which allows them to digest their way into CSPG-filled plaques, enhancing theirremyelination potential in models of MS (Luo et al.,2018). The gene discussed is MMP2; the disease is myeloid sarcoma.